IRWD
IronwoodANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Strong LINZESS net-price and demand execution is generating meaningful profitability and cash flow, while active STARS-2 recruitment provides a credible longer-term pipeline option. Pediatric LINZESS label expansion adds incremental commercial reach.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.3.
What can break
An officer reported an open-market sale of 127,890 shares at $4.52; this is an insider-activity signal only and does not establish an operating trend. [#SEC-FORM4-2026-07-09]
Momentum
75
Value
70
Sentiment
91
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.80 · Bull $8.50 · Bear $2.40
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.23
Why
Momentum75 · Δ7d -15.6
Value70 · Δ7d +0.4
Sentiment91 · Δ7d +11.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
75
26% active weight
Current posture
7d trendSoftening
Δ7d
-15.6
Δ21d
+33.0
Value
70
39% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.4
Sentiment
91
34% active weight
Current posture
7d trendImproving
Δ7d
+11.3
Δ21d
+24.1
Why this grade
Composite grade A. Momentum 75.3 / Value 70.3 / Sentiment 90.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$635.41M
Beta
0.16
Shares Out
164.61M
P/E (TTM)
32.7
P/S (TTM)
2.20
P/FCF (TTM)
11.04
Rev YoY
+158.9%
EPS YoY
-205.3%
Gross Margin
+99.5%
Op Margin
+36.3%
Net Debt
$382.35M
Current Ratio
1.41
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology